Japan's Eisai to buy US MGI Pharma for $3.9 bln Dec 11, 2007
MGI's products include Aloxi, a treatment to prevent chemotherapy-induced nausea; Gliadel Wafer, a drug delivery device in the treatment of brain cancer; and Dacogen, a treatment for a group of blood disorders known as myelodysplastic syndromes that often precedes leukemia. Big-ticket biotech deals this year include AstraZeneca (AZN.L: , , ) buying MedImmune for $15. (Reuters)
Pharmion Vidaza drug survival benefit confirmed Dec 11, 2007
BOSTON, Dec. 9 (Reuters) - Pharmion Corp (PHRM.O: , , ) said on Sunday that detailed analysis of a late-stage clinical trial of its drug to treat a group of blood disorders known as myelodysplastic syndromes confirmed it increased survival and improved quality of life. Data presented at the annual meeting of the American Society of Hematology confirmed that patients who were treated with Pharmion's drug Vidaza had a median survival advantage of 9. (Reuters)
Pharmion Presents Clinical Data Demonstrating Significant Survival Advantage of Vidaza(R) in Patients with Myelodysplastic Syndromes (MDS) Dec 10, 2007
2% for Conventional Care Regimens - Highly Consistent Effect Across Patient Subgroups - Data Presented at the 49th American Society of Hematology Meeting ATLANTA, Dec. 9 /PRNewswire-FirstCall/ -- Pharmion Corporation (Nasdaq: PHRM) today announced complete results from a Phase 3 multi-center, international, randomized study of Vidaza(R) (azacitidine for injection) in the treatment of patients with higher-risk myelodysplastic syndromes (MDS) demonstrating that Vidaza provides a significant... (PR Newswire)
Research Provides Critical Insight into Improving Therapy for Difficult-to-Treat Blood Cancers Dec 10, 2007
-- Study Identifies Potential Breakthrough in Treatment of Rare and Aggressive Form of Non- Hodgkin Lymphoma -- ATLANTA, Dec. 9 /PRNewswire-USNewswire/ -- Data that will have a significant impact on the treatment of patients with certain hard-to-treat lymphomas, myelomas, and myelodysplastic syndromes will be presented at the 49th Annual Meeting of the American Society of Hematology in Atlanta, GA. The data include a late-breaking abstract reporting long-standing remissions for patients with... (PR Newswire)
Possible Cure for Rare Lymphoma Reported Dec 10, 2007
And physicians from the Hospital Avicenne in Paris reported that a new drug, azacitidine, was more effective than standard chemotherapy at prolonging survival among 358 patients with high-risk myelodysplastic syndromes (MDS), which currently have no cure other than bone marrow transplantation. More information. (Health-Finder)
Ligand Presents Positive LGD-4665 Phase I Clinical Trial Results at the American Society of Hematology Annual Meeting (ASH) Dec 9, 2007
Based on its strong potency, convenience and potential for dosing flexibility, we believe that LGD-4665 could be used as treatment for a wide variety of diseases associated with thrombocytopenia, including hepatitis C, chemotherapy-induced thrombocytopenia (CIT), myelodysplastic syndromes (MDS), idiopathic thrombocytopenic purpura (ITP) and several other cancers and liver diseases ... Myelodysplastic Syndromes (MDS) - According to the Cleveland Clinic Foundation, 35,000 to 40,000 patients in the... (BusinessWire)
Help fund Gabe's medical costs Dec 8, 2007
Gabe Quiles-ColvinAccount for Myelodysplastic Syndromes. Bank Of America7770 W. Oakland Park Blvd.Sunrise, FL 33351. (WSVN-TV Miami, FL)
MGI Pharma hires bankers to evaluate alternatives Nov 30, 2007
MGI sells Dacogen, a treatment for a group of blood disorders known as myelodysplastic syndromes, or MDS, which often leads to leukemia. Dacogen competes with Pharmion's drug Vidaza. (San Diego Union-Tribune -- Business)
Pharmion CEO will stay in Colo., start another biotech Nov 21, 2007
Celgene will acquire the rights to Vidaza, a drug Pharmion sells domestically for advanced cases of myelodysplastic syndromes, a family of cancerous blood disorders that used to be dubbed pre-leukemia. Vidaza will complement Celgene's existing treatments for early-stage MDS.. (Denver Business Journal, CO)
Celgene to buy Pharmion for $2.9 billion Nov 20, 2007
In August, Boulder, Colorado-based Pharmion said a late-stage trial of its drug Vidaza significantly extended the life of patients with myelodysplastic syndromes, a group of blood disorders that can lead to leukemia. Its shares rose as much as 62 percent on the day in response. (ABC News -- Wire)
Celgene's Smart Buy Nov 20, 2007
It is also used to treat multiple myeloma, but it was approved first for a rare blood disorder, a version of a set of diseases called myelodysplastic syndromes (MDS) where part of a particular genetic chromosome is deleted. Pharmion's most successful drug, Vidaza, is also approved to treat MDS, but it is used in a far more severe form of the disease. (Forbes -- Business)
Celgene to acquire Pharmion Nov 19, 2007
Pharmion, based in Boulder, Colorado, also sells the drug Vidaza, which is used to treat myelodysplastic syndromes, or MDS, a group of bone marrow diseases that can lead to cancer. Celgene's Revlimid is also approved to treat MDS, as well as multiple myeloma, a form of blood cancer. (International Herald Tribune)
CombiMatrix Molecular Diagnostics Launches HemeScan MDS for the Management and Diagnosis of Myelodysplastic Syndromes Sep 25, 2007
HemeScan(tm) MDS (myelodysplastic syndromes) is designed to detect clonal prognostic markers in bone marrow aspirates from patients with refractory anemia combining diagnosis of pre-leukemia with individualized risk stratification and treatment planning. It is now available to the clinical community through both routine clinical sample processing as well as through CMDX's innovative Technical Only Program for reference laboratories. (Primezone Releases)
Ortho Biotech Supports FDA Advisory Committees' Recommendations on Use of ESAs in Chronic Renal Failure Patients Sep 12, 2007
-- The safety and efficacy of PROCRIT therapy have not been established in patients with a known history of a seizure disorder or underlying hematologic disease (eg, sickle cell anemia, myelodysplastic syndromes, or hypercoagulable disorders). -- In some female patients, menses have resumed following PROCRIT therapy; the possibility of pregnancy should be discussed and the need for contraception evaluated. (PR Newswire)
ProMetic Expands Indication for PBI-1402 Into Anemia In Cancer Patients Sep 12, 2007
More about Myelodysplastic Syndromes ("MDS"). MDS are a group of diseases in which the production of blood cells by the bone marrow is disrupted. (CCNMatthews Press Releases)
FDA fast-tracks Pharmion's blood disorder drug Aug 31, 2007
Pharmion (NASDAQ: PHRM) received FDA approval to market an injectible version of Vidaza in 2004 as a treatment for myelodysplastic syndromes, which inhibit the body's production of blood cells. The potentially life-threatening syndromes affect an estimated 10,000 to 20,000 Americans each year and is diagnosed mostly in people over 65. (Denver Business Journal, CO)
Andreessen's Opsware Burns Short Sellers as Takeover Pushes Shares Higher Aug 24, 2007
The injectable treatment, Vidaza, extended survival by 74 percent in a study of patients with higher-risk myelodysplastic syndromes, in which blood cells in bone marrow don't function normally, the company said. Impac Mortgage Holdings Inc. (IMH US) dropped 64 percent after 35 percent of its float was sold short. (Bloomberg)
European School of Haematology Launches Curriculum in Iron Metabolism & Related Disorders Jul 4, 2007
Myelodysplastic Syndromes. Thalassaemia (major and intermedia). (BusinessWire)
More of this story Jun 19, 2007
Jalbert has been suffering with Myelodysplastic syndromes (MDS) a group of myeloid stem cell disorders that gradually affect the ability of a person s bone marrow to produce normal cells such as red blood cells, white blood cells, and platelets. Patients with MDS have a risk of the disease progressing to acute myelogenous leukemia. (Westerly Sun, RI)
June 18: Friends host drive to aid local woman with leukemia Jun 19, 2007
Myelodysplastic Syndromes Facts & Statistics. The term myelodysplastic syndromes or MDS describes a group of blood cancers. (Westerly Sun, RI)
CMS Coverage Proposal for Erythropoiesis-Stimulating Agents (ESAs) Jeopardizes Cancer Clinical Practice and Patient Access Jun 14, 2007
g., sickle cell anemia, myelodysplastic syndromes, or hypercoagulable disorders). -- In some female patients, menses have resumed following PROCRIT therapy; the possibility of pregnancy should be discussed and the need for contraception evaluated. (PR Newswire)
'I've learned to live life day by day and take the good with the bad.' Jun 14, 2007
Myelodysplastic syndromes, or MDS, are a group of diseases that cause a person's bone marrow to stop producing enough healthy blood cells. Usually, bone marrow produces stem cells that develop into red blood cells, white blood cells and platelets. (Lodi News Sentinel, CA)
New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly Paclitaxel as Adjuvant Therapy for High Risk Breast Cancer Warranted in Place of Doxorubicin Plus Cyclophosphamide Followed by Paclitaxel Jun 5, 2007
D.: Phase II study of eribulin mesylate (E7389) halichondrin b analog in patients with refractory breast cancer -- Alexander Spira, M.D.: Phase II study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced Non-Small Cell-Lung Cancer (NSCLC) -- John Pippen, Jr., M.D., F.A.C.P.: "A Historical Overview of the Treatment of Prostate Cancer and the Evolution of Bone Marrow Transplantation" -- Marcus Neubauer, M.D., Co-Chair: Lung Cancer... (PR Newswire)
Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors Jun 3, 2007
"These studies will help provide us with insight not only into the continuing development of parenteral Vidaza, but, in particular, provide us direction for the development of oral azacitidine." Tolerability and hematologic improvement assessed using three alternative dosing schedules of azacitidine (Vidaza) in patients with Myelodysplastic Syndromes (MDS) - R. Lyons; Abstract #7083; June 2, 2007; 8am-12pm; McCormick Place Convention Center, S Hall A2) Interim results from a Phase II,... (PR Newswire)
Clinical Data Presented on Pilot Pharmacokinetic Study of Oral Azacitidine Jun 3, 2007
The study was designed to assess the safety, tolerability, and pharmacokinetics of escalating single doses of orally administered Azacitidine in patients with Myelodysplastic Syndromes (MDS), acute myeloid leukemia (AML) or other solid tumors ... "Oral azacitidine represents an extremely exciting opportunity," said Dr. Guillermo Garcia-Manero, Associate Professor of Medicine and Chief, Section of Myelodysplastic Syndromes, Department of Leukemia, M.D. Anderson Cancer Center ... "The potential... (PR Newswire)
Pharmion and MethylGene Report Preliminary Data for MGCD0103 at the 43rd American Society of Clinical Oncology (ASCO) Annual Meeting Jun 3, 2007
HDAC Inhibitor MGCD0103 Demonstrates Substantial Response Rate In Two Clinical Trials 40% Response Rate and 45% Disease Control Rate in Single-Agent Phase II Trial in Refractory or Relapsed Hodgkin's Lymphoma Patients 30% Response Rate (37% at Relevant Active Doses) in Phase I/II Combination Trial with Vidaza(R) in MDS and AML Patients CHICAGO, June 2 /PRNewswire-FirstCall/ -- Pharmion Corporation (Nasdaq: PHRM) and MethylGene Inc. (TSX: MYG) today announced preliminary Phase II and Phase I/II... (PR Newswire)
Pharmion to Present Clinical Data on Commercial and Pipeline Products at 2007 American Society of Clinical Oncology (ASCO) Meeting Jun 1, 2007
These abstracts include summaries of data from studies of each of the six key products in the company's commercial and development portfolio, for multiple indications, including Myelodysplastic Syndromes (MDS), multiple myeloma, Hodgkin's lymphoma, small cell lung cancer and advanced hormone-refractory prostate cancer ... The following clinical data will be presented in poster sessions (unless otherwise noted) during the ASCO 2007 annual meeting: Vidaza(R) Tolerability and hematologic... (PR Newswire)
HRT Linked to Ovarian Cancer Deaths in the Britain Apr 20, 2007
By Judith Groch, Senior Writer, MedPage Today Reviewed by April 19, 2007. OXFORD, England, April 19 -- Use of hormone replacement therapy for at least five years added up to 1,300 additional ovarian cancers over 14 years in Britain and 1,000 extra deaths, researchers here reported. (MedPage Today)
EDITORIAL: The real cancer threat Mar 28, 2007
Revlimid -- a drug that eliminates the use of expensive blood transfusions for nearly 75 percent of patients with myelodysplastic syndromes that causes underproduction of red blood cells -- has been available in the United States since 2005. Canada has yet to make it available while it "negotiates" a "cost-effective" price. (Washington Times)
Online tool helps physicians improve care of patients with bleeding disorder Feb 8, 2007
PIMs are available on myelodysplastic syndromes and multiple myeloma, in addition to ITP. Each PIM provides board-certified physicians enrolled in the Maintenance of Certification program 20 practice improvement points, as well as 20 Category 1 continuing medical education (CME) credits. Hematologists may also earn 60 Maintenance of Certification points and 37. (EurekAlert! -- Business News)
Aplastic Anemia: A Rare Disease With a Better Prognosis Feb 4, 2007
A related blood disorder, myelodysplastic syndromes, or MDS, occurs when the bone marrow begins producing poorly functioning or immature blood cells. About 20,000 to 30,000 new cases occur each year. (Health-Finder)
FDA OKs Pharmion drug delivery Jan 30, 2007
The FDA first approved Vidaza from treating five types of Myelodysplastic Syndromes (MDS) in 2004. MDS is a bone marrow disorder characterized by the production of abnormally functioning, immature blood cells. (Denver Business Journal, CO)
The New England Journal Of Medicine Publishes Two Landmark Studies Of NOXAFIL(R) (Posaconazole) in the Prevention of Invasive Fungal Infections Jan 25, 2007
These patients included hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD) or those with hematologic malignancies such as acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS) with prolonged neutropenia from chemotherapy. In high-risk neutropenic patients, NOXAFIL prophylaxis was associated with decreased all-cause mortality versus the combined comparator drugs. (PR Newswire)
Role For Proteomics In Identifying Hematologic Malignancies Jan 16, 2007
Scientists have identified a set of biomarkers that could help clinicians identify a group of hematologic malignancies known as myelodysplastic syndromes (MDS), which affect approximately 300,000 individuals worldwide and often progress to acute myeloid leukemia. Reported in the advance issue of the Proceedings of the National Academy of Sciences (which appears on-line the week of January 8) the findings point to a possible new diagnostic method for these malignancies, which occur when blood... (Science Daily)
Sutent and Nexavar Put Brakes on Renal-Cell Carcinoma Jan 11, 2007
Designed for pharmacists who care for patients with myelodysplastic syndromes (MDS) or multiple myeloma (MM), this CPE webcast explores several new and emerging agents that have shown promising results in treating these challenging cancers. Source: Projects In Knowledge')"> | | | ? 2004-7 MedPage Today, LLC. All Rights Reserved.. (MedPage Today)
Cancer Linked to Abnormal Number of Chromosomes Dec 30, 2006
By Michael Smith, Senior Staff Writer, MedPage Today Reviewed by December 28, 2006. Dec. 28 -- A century ago, a German biologist named Theodor Boveri suggested that one of the causes of cancer was aneuploidy. (MedPage Today)
Temporary Brain Shrinkage May Explain 'Chemobrain' Nov 28, 2006
Temporary Brain Shrinkage May Explain Chemobrain - CME Teaching Brief - MedPage Today. Temporary Brain Shrinkage May Explain 'Chemobrain. (MedPage Today)
Pharmion and Nippon Shinyaku Announce Licensing Agreement for Vidaza(R) in Japan Nov 21, 2006
"Nippon Shinyaku's proven track record in the area of oncology makes them a good partner for Pharmion," said Patrick J. Mahaffy, Pharmion's president and CEO. "This licensing partnership validates the potential for Vidaza in Japan." Vidaza is marketed by Pharmion Corp. in the U.S., and by distributor partners in the other four countries where Vidaza is approved for the treatment of Myelodysplastic Syndromes (MDS): Israel, the Philippines, South Korea and Switzerland ... About Vidaza On May 19,... (PR Newswire)
Drug startup to be acquired for $59 million Nov 17, 2006
Pharmion, which is based in Boulder, is best known for its drug Vidaza, a treatment for myelodysplastic syndromes. Though the company has yet to turn a profit, it had sales of $178. (San Diego Union-Tribune -- Business)
Noxafil(R) (Posaconazole) Oral Suspension Approved in European Union for Prevention of Invasive Fungal Infections Nov 9, 2006
Treatment of Oropharyngeal Candidiasis (OPC) Also Approved KENILWORTH, N.J., Nov. 9 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: ) today announced that the European Commission has granted marketing approval to NOXAFIL(R) (posaconazole) Oral Suspension for prophylaxis (prevention) of invasive fungal infections (IFIs) in the following patients at high risk of developing these infections: patients receiving remission-induction chemotherapy for acute myelogenous leukemia (AML) or... (PR Newswire)
Tekne Award winners announced Oct 28, 2006
Bloomington, for an injection that can be used to treat patients diagnosed with myelodysplastic syndromes. Software developer , Eden Prairie, for its development of Site Studio, which enables customers to more easily manage thousands of corporate Web sites. (Twin Cities Business Journal, MN)
Moffitt research on myelodysplastic syndromes appears in New England Journal of Medicine Oct 6, 2006
5 , 2006) -- H. Lee Moffitt Cancer Center rch Institute announced publication of the final results from a pivotal Phase II trial of Revlimid in patients with an incurable blood cancer know as myelodysplastic syndromes (MDS) in the October 5 issue of the New England Journal of Medicine. The data published found that more than 75 percent of patients reduced their need for transfusions and two-thirds were completely freed from the need for transfusions. (EurekAlert!)
Clinical Data From REVLIMID(R) Study in Myelodysplastic Syndromes Reported in New England Journal of Medicine Oct 5, 2006
SUMMIT, N.J., Oct. 4 /PRNewswire-FirstCall/ -- The New England Journal of Medicine today published final results of a Celgene Corporation (Nasdaq: CELG) sponsored Phase II trial evaluating REVLIMID(R) (lenalidomide) as an oral therapy for patients with myelodysplastic syndromes (MDS) with transfusion- dependent anemia and deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities ... REVLIMID is also indicated for treatment of patients with transfusion-dependent... (PR Newswire)
European Union's CHMP Adopts Positive Opinion for NOXAFIL(R) (posaconazole) Oral Suspension for Prevention of Invasive Fungal Infections Sep 22, 2006
Treatment of Oropharyngeal Candidiasis (OPC) Also Recommended for Approval KENILWORTH, N.J., Sept. 22 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: ) today reported that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) issued a positive opinion recommending approval of NOXAFIL(R) (posaconazole) Oral Suspension for prophylaxis (prevention) of invasive fungal infections (IFIs) in the following patients at high risk of developing these... (PR Newswire)
No More Needles - A New Breakthrough for Iron Overload Sep 21, 2006
"The approval of Exjade marks the beginning of an exciting new era for iron chelation therapy." Notes to Editors Iron Overload Iron overload is a cumulative, potentially life threatening and unavoidable consequence of frequent blood transfusions used to treat certain chronic blood disorders such as thalassaemia, sickle cell disease and myelodysplastic syndromes (MDS) ... The studies demonstrated that Exjade at 20-30 mg/kg/day led to the maintenance or reduction of iron burden in transfused... (PR Newswire)
New hope in cancer vaccines emerges as novel therapies are developed and tested Aug 6, 2006
The PR1 peptide vaccine is slated to be tested at M. D. Anderson in other kinds of leukemia of myeloid origin, such as acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), and pre-leukemic myelodysplastic syndromes. A vaccine can even be useful in patients who respond well to treatment, says Cortes, because even the best therapies may not eliminate all traces of disease. (EurekAlert!)
SuperGen gets boost with Dacogen deal Jul 8, 2006
The Food and Drug Administration approval in May made Dacogen the third medicine in the U.S. for myelodysplastic syndromes, in which the body fails to produce mature blood cells and leaves patients vulnerable to anemia and infections ... More than 10,000 Americans are diagnosed with myelodysplastic syndromes each year, according to the American Cancer Society. (Inside Bay Area, CA)
MGI Pharma inks $80M license with J & J Jul 7, 2006
Dacogen is given to patients with myelodysplastic syndromes (MDS) which occur when there is a defect in the blood-forming stem cells, resulting in too few and poorly functioning blood cells. The product was approved by the U.S. Food and Drug Administration on May 2. (Twin Cities Business Journal, MN)
Online Buying Moves Quickly Up The Line Jul 4, 2006
In December the Summit, N.J.-based firm won FDA approval to sell Revlimid, a pill for patients with anemia caused by Myelodysplastic Syndromes, which can lead to cancer. Revlimid and Thalomid have similar characteristics, says analyst Howard Liang of Leerink Swann. (Investors Business Daily)
MMRF Applauds FDA Approval Of REVLIMID(R) for Multiple Myeloma Jun 30, 2006
(R) It is also approved by the FDA for treatment of patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. About the Multiple Myeloma Research Foundation (MMRF) The Multiple Myeloma Research Foundation (MMRF) was established in 1998 as a 501(c)3 non-profit organization by twin sisters Karen Andrews and Kathy Giusti, a newly diagnosed... (PR Newswire)
REVLIMID(R) in Combination With Dexamethasone sNDA Granted Approval By FDA for Treatment of Multiple Myeloma Jun 30, 2006
REVLIMID is also approved for use in the treatment of patients with transfusion-dependent anemia due to Low-or- Intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities ... THIS DRUG IS ASSOCIATED WITH SIGNIFICANT NEUTROPENIA AND THROMBOCYTOPENIA. EIGHTY PERCENT OF PATIENTS WITH DELETION 5Q MYELODYSPLASTIC SYNDROMES HAD TO HAVE A DOSE DELAY/REDUCTION DURING THE MAJOR STUDY. THIRTY-FOUR PERCENT OF... (PR Newswire)
A family divided, a family united: 4-year-old’s medical roller coaster ride sends him far from home for treatment, but his family rallies around him Jun 8, 2006
Liam was diagnosed last October with myelodysplastic syndromes (MDS) and monosomy 7. MDS is a collection of disorders in which the bone marrow does not produce enough blood cells, according to the MDS Foundation. (Muscatine Journal, IO)
FDA CAPSULES May 16, 2006
NEW DRUG FOR BONE MARROW DISORDER. The FDA has approved Dacogen, an injectable drug for myelodysplastic syndromes, a group of rare disorders in which the bone marrow does not produce enough mature blood cells. www. (Newsday -- Health)
Lenalidomide and Venous Thrombosis in Myeloma May 11, 2006
1 It has recently been approved by the Food and Drug Administration for certain myelodysplastic syndromes associated with a chromosome 5q deletion. We report on the risk of thrombosis when lenalidomide is used with other agents that have known thrombogenic potential, including erythropoietin, and the need to consider antithrombotic prophylaxis when such combinations are administered. (New England Journal of Medicine)
SuperGen bone marrow drug gets FDA approval May 8, 2006
The approval comes more than seven years after SuperGen began studying Dacogen, a drug that could reduce or eliminate the need for patients with myelodysplastic syndromes, or MDS, to undergo frequent blood transfusions. The approval triggers a $20 million milestone payment to SuperGen. (East Bay Business Times, CA)
Dacogen comes to the rescue of MDS May 7, 2006
Myelodysplastic syndromes (MDS) is a type of disorder in which in which the bone marrow stops producing mature Red blood cells (RBC). Due to this the patients lack enough number of RBCs and resulting in improper functioning of the body. (MedIndia)
New Treatment for Bone Marrow Disorders May 5, 2006
WEDNESDAY, May 3 (HealthDay News) -- An injectable drug to treat a group of rare bone-marrow disorders called myelodysplastic syndromes (MDS) has been approved by the U.S. Food and Drug Administration. Dacogen (decitabine) was sanctioned to treat the estimated 7,000 to 12,000 cases of MDS diagnosed each year in the United States, the agency said in a statement. (MEDLINEplus)
FDA OKs bone marrow drug May 4, 2006
The Food and Drug Administration said Dacogen would provide an additional treatment option for patients suffering from myelodysplastic syndromes ... There are different types of myelodysplastic syndromes, which can develop following treatment with drugs or radiation for other diseases ... Myelodysplastic syndromes are most common in the elderly. (MSNBC -- Health)
FDA Approves New Treatment for Myelodysplastic Syndromes (MDS) May 4, 2006
FDA Approves New Treatment for Myelodysplastic Syndromes (MDS) ... FDA Approves New Treatment for Myelodysplastic Syndromes (MDS) ... The Food and Drug Administration (FDA) today approved Dacogen (decitabine) injection for the treatment of myelodysplastic syndromes (MDS). (U.S. Food and Drug Administration)
MN Company Gets Approval For New Bone Marrow Drug May 4, 2006
The Food and Drug Administration says Dacogen provides an additional treatment option for patients suffering from myelodysplastic syndromes. Dacogen is made by a Dutch company for MGI Pharma Incorporated of Bloomington, Minn. (WCCO.com, MN)
SuperGen, MGI Pharma get FDA approval for MDS drug May 4, 2006
and partner have received regulatory approval for an injectable drug that treats myelodysplastic syndromes, a group of diseases affecting bone marrow, the companies announced Wednesday. The companies plan to have the drug on the market in the second quarter of this year. (East Bay Business Times, CA)
Clinical Trials Update: April 24, 2006 Apr 25, 2006
Myelodysplastic Syndromes (MDS). "> A Service of the National Health Information Center, U.S. Department of Health Human Services | > Clinical Trials Update: April 24, 2006 Schizophrenia and Schizoaffective Disorders Excessive Sweating Myelodysplastic Syndromes (MDS) this article to news Clinical Trials Update: April 24, 2006 this news article. Subscribe to . --> (HealthDay News) -- Here are the latest clinical trials, courtesy of CenterWatch: Schizophrenia and Schizoaffective Disorders This... (Health-Finder)
Orphan Drug Designation Granted by the U.S. FDA for Ceflatonin(R) Mar 20, 2006
Ongoing or soon to be initiated clinical trials are and will be evaluating Ceflatonin in a broad range of conditions, including: chronic myeloid leukemia (CML), myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Orphan drug status is granted by the FDA to promote the development of drugs for diseases affecting less than 200,000 people in the United States. (PR Newswire)
New drugs improve bone marrow cancer outlook Mar 13, 2006
Article: "Decitabine Improves Patient Outcomes in Myelodysplastic Syndromes: Results of a Phase III Randomized Study," Hagop Kantarjian, Jean-Pierre J. Issa, Craig S. Rosenfeld, John M. Bennett, Maher Albitar, John DiPersio, Virginia Klimek, James Slack, Carlos de Castro, Farhad Ravandi, Richard Helmer III, Lanlan Shen, Stephen D. Nimer, Richard Leavitt, Azra Raza, Hussain Saba, CANCER; Published Online: March 13, 2006 (DOI: 10. 1002/cncr. (EurekAlert!)
Treatable condition Feb 16, 2006
Similarly, he added, Celgene's Revlimid, currently approved for certain types of myelodysplastic syndromes, could get approval later this year for treatment of multiple myeloma. Celgene is an "earnings leverage story," Patten said. (CBS MarketWatch - Front Page)
